CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 159 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Clopidogrel 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02217501
NCT02217501Phase 3Completed
CompareCT.gov

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

University of Texas Southwestern Medical Center·interventional·Posted Aug 15, 2014·Updated Feb 21, 2021

In Brief

A Phase 3 clinical trial evaluating Clopidogrel and Acetylsalicylic acid (ASA) for Peripheral Arterial Disease. Completed, enrolled 159 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate whether clopidogrel 75 mg daily on a background of aspirin 75-100 mg/d for clinically indicated duration or for an additional 12 months will lead to an increased rate of primary patency, limb salvage, non-fatal myocardial infarction (MI), ischemic stroke, and survival, in patients receiving endovascular treatment of PAD at end of study treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 15, 2014
Enrollment StartNov 1, 2015
Primary CompletionJan 30, 2020
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.9 years ago

Interventions

Clopidogreldrug

Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months

Acetylsalicylic acid (ASA)drug

Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months